ReviewFEBS open bio2026
Patatin-domain-containing (phospho)lipases under control: Mammalian co-regulators and pathogenic activation mechanisms.
Review in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Highlights of the FEBS3+ meeting Exploring molecular frontiers.FEBS open bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Patatin-like phospholipase (PNPLA) domain-containing proteins are essential enzymes involved in lipid metabolism, membrane remodeling, and signaling pathways across various organisms. This review focuses on the structural and functional characteristics of four selected PNPLA proteins from different organisms with experimental 3D structures or biochemical data on protein-protein interactions that facilitate their co-activation mechanism, namely VipD, ExoU, PNPLA9, and PNPLA2 (also known as ATGL). VipD and ExoU, phospholipases from Legionella pneumophila and Pseudomonas aeruginosa, respectively, are multidomain proteins and utilize distinct mechanisms for host cell interaction and pathogenesis. VipD binds to Rab proteins, underscoring the critical role of Rab5 in upregulating its enzymatic activity and contributing to the pathogenicity. ExoU requires ubiquitin for activation and exhibits an inhibited structure when complexed with its chaperone SpcU. PNPLA9, a calcium-independent phospholipase A2, is predominantly expressed in the human brain, with mutations linked to neurodegenerative disorders and inflammation. The crystal structure of the Chinese hamster ortholog of PNPLA9 reveals a dimerization mechanism required for its catalytic activity, along with specific regions identified for membrane interaction and substrate binding. PNPLA2 is known for its triacylglycerol hydrolytic activity and is regulated by protein-protein interactions, particularly with the co-activator ABHD5, which is crucial for its activation. This review highlights the diversity and conserved architectural segments of PNPLA proteins, reflecting their varied biological roles and regulatory mechanisms. Understanding the diverse protein-protein interactions that activate these enzymes is crucial for elucidating their roles in physiological and pathological contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.